PRODIGE 7 Trial: Key Findings and Clinical Implications

Primary Trial Results

The American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) recommend cytoreductive surgery (CRS) plus systemic chemotherapy without hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with colorectal peritoneal metastases, based on the PRODIGE 7 trial results showing no survival benefit and increased late complications with HIPEC 1, 2, 3, 4
The PRODIGE 7 trial demonstrated that adding 30-minute oxaliplatin-based HIPEC to CRS provides no survival benefit and increases late complications in patients with colorectal peritoneal metastases 1

Overall survival was identical between groups (HR 1.00; 95% CI 0.63-1.58), with no difference in relapse-free survival (HR 0.91; 95% CI 0.71-1.15) 1
15% of patients remained progression-free at 5 years, indicating CRS may be curative in appropriately selected patients, regardless of HIPEC addition 2, 5

HIPEC significantly increased late complications without improving outcomes, with a relative risk of 1.69 (95% CI 1.03-2.77) for grade 3+ adverse events at 60 days post-operatively 1

The American Society of Clinical Oncology (ASCO) recommends CRS plus systemic chemotherapy without HIPEC for selected patients with isolated colorectal peritoneal metastases 2, 3, 4
The European Society for Medical Oncology (ESMO) does not recommend HIPEC as standard of care for colorectal peritoneal metastases, citing the absence of overall survival benefit and more frequent post-operative late complications 3, 4

Complete macroscopic cytoreduction is the most critical factor affecting long-term survival, with only 1 of 18 patients with complete tumor resection having died after a median follow-up of 21.6 months 1, 2, 5
Patients should have isolated peritoneal metastases with no extraperitoneal disease, be amenable to complete macroscopic cytoreduction, and have treatment at specialized centers with substantial CRS experience 2, 5

Multidisciplinary team management is mandatory and must include medical oncology expertise, surgical oncology with CRS experience, radiology, and pathology 2, 5

The American Society of Clinical Oncology recommends that complete cytoreductive surgery (CRS) plus systemic chemotherapy is the recommended treatment for selected patients with isolated colorectal peritoneal metastases, but the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) is not recommended based on the latest high-quality evidence 6, 7

The American Society of Clinical Oncology suggests that CRS should only be considered in patients who meet all the following criteria: isolated peritoneal metastases without extraperitoneal disease, possibility of complete macroscopic cytoreduction, and treatment in specialized centers with substantial experience 6, 7, 8

The National Comprehensive Cancer Network recommends an initial evaluation by a multidisciplinary team, followed by neoadjuvant systemic chemotherapy based on molecular characteristics, and then complete cytoreductive surgery without HIPEC 6, 8, 9
The European Society for Medical Oncology suggests that patients with potentially resectable disease should receive neoadjuvant systemic chemotherapy, followed by complete cytoreductive surgery, and then adjuvant systemic chemotherapy 6, 7, 9

The American Joint Committee on Cancer states that the most important factor for long-term survival is the completeness of cytoreduction, with CC-0 (no residual disease) being associated with the best prognosis 6, 7

The American Society of Clinical Oncology warns that the mortality rate related to treatment was 8% in historical studies of CRS + HIPEC, and that HIPEC may only affect the superficial layers of the peritoneal surface, being effective only in scenarios of minimal residual disease 6, 7

The National Institute for Health and Care Excellence recommends that shared decision making should include discussion of the potential impact on quality of life, the rate of adverse events associated with CRS, the need for treatment in a specialized center, and realistic expectations, with only 15% of patients being free of progression at 5 years 6, 7, 8